Dr. David Morgan Accepts Board Seat; Peter Whitehead Becomes CEO as August Bolsters Management

Vancouver, BC, CANADA

LAS VEGAS, May 2, 2003 (PRIMEZONE) -- August Biomedical Corp. (OTCBB:AGBM) ("August") is pleased to announce the appointment of Dr. David Morgan to its Board of Directors.

Dr. David Morgan obtained his PhD in Physics at the University of British Columbia and then had research positions at the University of Cambridge and at the British Columbia Cancer Agency (BCCA) before joining Biomax Technologies Inc., a medical device company, in 1997.

While at Biomax, he was the Project Manager for the Optical Catheter System, a computer controlled diagnostic device designed to detect rejection in patients having undergone hearing transplantation by measuring the laser induced auto fluorescence of the tissue in the right ventricle of the heart. In 2001, he was hired as Engineering Manager and subsequently became Vice President of Engineering at MDMI Technologies Inc., a company focusing on therapeutic devices in the gynecological and cardiovascular areas as well as contract manufacturing of medical devices.

He has over five years experience in medical device companies and will help plan and direct its product development activities.

Peter Whitehead has become the visionary driving force behind August. He assumes the role of CEO effective immediately. Mr. Whitehead brings years of experience in medical research and biophysics with the BCCA combined with expertise in biomedical product development in the field of cardiology. His work has been published in peer reviewed journals such as Circulation, the world's largest cardiology journal. He is responsible for 15 patents filed ranging from molecular biology to cardiovascular surgery of which 3 awarded patents have rendered human testing.

His well known patent work inventing fluorescence image based cardiac transplant rejection monitor products bridges well with August's proprietary fluorescence imaging technologies that aim to penetrate the oral and cervical cancer screening/diagnostic markets.

The Board of Directors has accepted the resignation of Mr. Scott Houghton as CEO.


AUGUST Biomedical Corp. (www.augustbio.com) is a medical technology company that develops manufactures and markets next generation proprietary dental and surgical imaging systems and devices aiding in the detection and localization of oral and cervical cancer.

This document may contain certain forward-looking statements regarding August Biomedical Corp. including statements about its operations, prospects and expectations about future financial results, including, but not limited to, future revenues and earnings. The words "estimate", "possible", "expects", "anticipates", believes", "seeking", and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. These forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially and are subject to change at any time. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including those risks and uncertainties detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2001 filed with the SEC as well as subsequent forms B-K's, 10-Q's, 14-C and S-8 registrations.

 For further information please call: